News & Events

Merus enters into 72.8 million euro series C financing led by Sofinnova Ventures and Novo A/S

August 27, 2015
UTRECHT, Netherlands, Aug. 26, 2015 - Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it has entered into an agreement with i...
Read more

Merus Prevails in Inequitable Conduct Case Against Regeneron

August 10, 2015
• Court ruling further strengthens Merus' freedom to operate in using transgenic mice for therapeutic human antibodies Utrecht, The Netherlands, August 10, 2015 -- Merus, a leader in developing best-in-clas...
Read more

Towards a Best Practice Approach in Cancer Immunotherapy: Cancer Vaccines Gain Momentum

July 28, 2015
• Review in The Journal of Clinical Investigation points the way forward for therapeutic cancer vaccines Leiden, The Netherlands, July 28, 2015 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy com...
Read more

ISA Pharmaceuticals Further Strengthens IP Position on Lead Compound ISA101

June 23, 2015
• Three additional European patents and market exclusivity granted for the use of key active ingredients of ISA101 Leiden, The Netherlands, June 23, 2015 - ISA Pharmaceuticals B.V., a clinical-stage immun...
Read more

Merus appoints Mark Iwicki as President of the Supervisory Board

June 01, 2015
Utrecht, The Netherlands, June 1, 2015 -- Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, today announced that Mark Iwicki has been appointed as Pr...
Read more

New Peer-Reviewed Publication Provides Further Insights into Mechanism of ISA Pharmaceuticals’ SLP® Immunotherapeutics

May 15, 2015
SLP®s modulate intratumoral macrophages required for tumor regression Leiden, The Netherlands, May 12, 2015 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally design...
Read more

Successful product lead identification underscores the strength of Merus’ platform in delivering human, full-length IgG bispecific antibodies

April 08, 2015
Utrecht, The Netherlands, 8th April 2015 - Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics, announced today that it has reached a preclinical milestone in a bispecific antib...
Read more

ISA Pharmaceuticals Granted European Patent for the Intradermal Administration of ISA101

March 26, 2015
- Intradermal administration provides significant benefits compared to subcutaneous application - Leiden, The Netherlands, March 24, 2015 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company...
Read more

ISA Pharmaceuticals announces start of first Phase I/II clinical trial of its SLP®-AMPLIVANT® conjugates

March 02, 2015
• Leiden University Medical Center to study novel immunotherapeutic in HPV-positive head & neck cancer patients Leiden, The Netherlands, February 26, 2015 - ISA Pharmaceuticals B.V., a clinical-stage immu...
Read more

Merus starts Phase I/II clinical trial for MCLA-128, an ADCC-enhanced bispecific antibody for solid tumors

February 06, 2015
- First patient dosed in trial with potent bispecific antibody overcoming resistance to HER2-targeted therapies - Utrecht, The Netherlands, February 4, 2015 -- Merus B.V., a leader in developing best-in-c...
Read more

New Study Explains Synergy between Cancer Vaccine ISA101 and Chemotherapy

January 09, 2015
Tumor necrosis factor alpha (TNFα) produced by T cells following vaccination sensitizes tumor cells for eradication by certain chemotherapeutics Data published in Clinical Cancer Research support ongoing c...
Read more

After US court ruling, Merus reaffirms freedom to operate for its MeMo® transgenic mouse for therapeutic human antibodies

January 06, 2015
- Regeneron's '018 patent' is considered invalid and Merus not infringing - Utrecht, The Netherlands, January 5, 2015 - Merus B.V., a leader in developing best-in-class antibody therapeutics to treat canc...
Read more

Issuance of a new U.S. patent covering ORCA’s T1 oncolytic adenovirus technology

January 06, 2015
Nijmegen, The Netherlands - January 5th, 2015 - ORCA Therapeutics BV, a pioneer in the development of innovative oncolytic immunotherapies for treatment of cancer, announced today that it has secured key int...
Read more

Publication in Nature Supports ISA Pharmaceuticals´ Synthetic Long Peptide Immunotherapeutic Approach to Treat Cancer

November 27, 2014
- Synthetic Long Peptide (SLP®) immunotherapy achieves targeted tumor eradication comparable to checkpoint-blocking immunotherapy - New findings on antigens relevant for checkpoint blocking pave the way for...
Read more

Publication Demonstrates Strong Preclinical Efficacy of ORCA's lead Compound ORCA-010 in Different Tumor Models

September 25, 2014
Nijmegen, The Netherlands - September 25th, 2014 - ORCA Therapeutics BV, a pioneer in the development of innovative oncolytic virus immunotherapies for treatment of cancer, announced today the publication of...
Read more

Patent Position of Merus' MeMo Mouse Strengthened by Ruling of European Patent Office

September 24, 2014
- Freedom to operate confirmed - Successful opposition against Regeneron's patent EP 1 360 287 B1 for transgenic mice producing therapeutic human antibodies Utrecht, The Netherlands, Sept. 18, 2014 - Merus...
Read more

Biotech venture capital firm Aglaia launches new $65 mln Oncology fund

September 18, 2014
Bilthoven, the Netherlands, 18 September 2014 - Dutch venture capitalist Aglaia has announced the launch of Aglaia Oncology Fun...
Read more
Biotech venture capital firm Aglaia launches new $65 mln Oncology fund

Biotech durfinvesteerder Aglaia start nieuw Oncology Fund met initieel 50 miljoen euro aan kapitaal

September 18, 2014
Bilthoven, 18 september 2014 - Durfinvesteerder Aglaia maakt de start bekend van een nieuw oncologiefonds onder de naam Aglaia Oncology Fund II. Investeerders participeren voor € 50 miljoen. De geplande fon...
Read more

ISA Pharmaceuticals Appoints Hendrik-Jan Laseur as Member of the Supervisory Board

September 03, 2014
ISA Pharmaceuticals Appoints Hendrik-Jan Laseur as Member of the Supervisory Board Leiden, The Netherlands, September 3, 2014 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on r...
Read more

Provincie benut kapitaal uit de markt voor Utrechtse Life Sciences sector

July 10, 2014
De provincie Utrecht heeft Aglaia Biomedical Ventures als professionele fondsbeheerder geselecteerd in het kader van een mandaat voor het aanwenden van € 1.25 miljoen voor ondernemingen in de Utrechtse Life...
Read more

Home > News & Events > Archive

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds